Navigation Links
Thesan Pharmaceuticals udpeger Dr. Bhaskar Chaudhuri til bestyrelsen i august 2014
Date:8/25/2014

SAN DIEGO, 25. august 2014 /PRNewswire/ -- Thesan Pharmaceuticals meddelte i dag, at firmaet udpeger Bhaskar Chaudhuri Ph.D. til bestyrelsen. Dr. Chaudhuri har mere end 25 års erfaring i ledelse inden for lægemidler, medicinsk forskning og udvikling og markedsføring i USA, EU og nye markeder. Han har ledet udviklingen og FDA-godkendelsen af flere NDA'er og ANDA'er. Senest var Dr. Chaudhuri adm. direktør for Valeant Phamaceutikals, før han blev arbejdende partner i Frazier Healthcare. Før Dr. Chaudhuri kom til Valeant var han adm. direktør for Dow Pharmaceuticals i perioden op til dette firmas opkøb af Valeant. Før Dow arbejdede Dr. Chaudhuri hos Bertek Pharmaceuticals (et datterselskab af Mylan Laboratories) som viceadm. direktør for videnskab og som direktør for dermatologiafdelingen hos Mylan Laboratories. Dr. Chaudhuri har et doktorat i fysisk farmakopé. Har er også medlem af bestyrelsen for flere lægemiddelselskaber.

"Vi er glade for at få Bhaskar i bestyrelsen på nuværende tidspunkt", sagde Gordon Foulkes, Thesan's adm. direktør. "Hans fantastiske CV inden for udvikling af dermatologimidler, hans markedsføringsekspertise og lederrolle i salget af flere dermatologiselskaber vil blive en fantastisk hjælp hos Thesan, når vi starter på at bygge et lederteam op for fremtiden".

"Jeg er helt klart beæret over at blive et medlem af Thesan-teamet", tilføjede Dr. Chaudhuri. Den aktuelle portefølje af banebrydende produkter, der ledes af et team af verdensklasse, giver Thesan grundlag for at være et ekstraordinært dermatologiselskab. Jeg ser frem til at bidrage til Thesans vækst og blive en del af en førende dermatologiorganisation".

Samtidig og i forbindelse med den nylige Serie B-finansiering vil Dr. Peter Moldt fra Novo Ventures blive det nye Novo-bestyrelsesmedlem, som repræsentant for dette firmas investering i Thesan. Dr. Moldt har masser af erfaring inden for bioteknologi og har været enten adm. direktør, produktionsdirektør eller udviklingschef i en række succesfulde selskaber, herunder Curalogic A/S, som han grundlagde og senere bragte på børsen i 2006. Dr. Moldt kom til Novo Ventures i 2009.

Om Thesan Pharmaceuticals, Inc.

Thesan er et bioteknologisk selskab, der fokuserer på udviklingen og markedsføringen af ny medicin til behandling af dermatologiske lidelser.
Flere oplysninger kan fås på: www.thesanpharma.com

Kontakt:
J. Gordon Foulkes, Ph.D.
Administrerende direktør
Thesan Pharmaceuticals, Inc.
Info@ThesanPharma.com


'/>"/>
SOURCE Thesan Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing
2. Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody
3. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
4. Global Medical Imaging Reagents (Nanoparticles, Fluorescent Proteins, Fluorescent Dyes and Probes, Radiopharmaceuticals and Quantum Dots) Market - Forecast to 2019
5. Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
6. OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer
7. RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell
8. RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars
9. Galmed Pharmaceuticals Reports First Half 2014 Financial Results
10. SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
11. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/9/2017)... ... , ... The award-winning American Farmer television series will feature 3 Bar Biologics ... at 8:30aET on RFD-TV. , With global population estimates nearing ten billion people ... to feed a growing nation. At the same time, many of our valuable resources ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ... INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will ... free and open to the public, but registration is required. , WHAT: ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):